Source comparison
5-Amino-1MQ and MOTS-c: Full Mechanism Comparison
Molecular Class Synthetic small-molecule enzyme inhibitor (quinolinium derivative) Mitochondrial-derived peptide (16 amino acids, encoded by mtDNA 12S rRNA) Completely different chemical structures. Not interchangeable Primary Target Nicotinamide N-methyltrans
This comparison does not assign a generated winner or score.
- Molecular Class
- Synthetic small-molecule enzyme inhibitor (quinolinium derivative)
- Mitochondrial-derived peptide (16 amino acids, encoded by mtDNA 12S rRNA)
- Completely different chemical structures. Not interchangeable
- Primary Target
- Nicotinamide N-methyltransferase (NNMT) enzyme in adipose tissue and liver
- AMPK (AMP-activated protein kinase) pathway via direct nuclear translocation
- Different regulatory nodes. Enzyme inhibition vs signaling activation
- Mechanism of Action
- Competitive inhibition of NNMT → preserves nicotinamide → increases NAD+ salvage → activates sirtuins (SIRT1/3) → enhances mitochondrial function
- Mitochondrial secretion → nuclear translocation → AMPK activation → GLUT4 translocation → insulin-independent glucose uptake + mTOR inhibition
- 5-Amino-1MQ is upstream (substrate availability); MOTS-c is downstream (metabolic signaling)
- Effect on NAD+ Levels
- Increases NAD+ by 40–50% in adipose tissue (rodent data) by preventing nicotinamide methylation
- No direct effect on NAD+. Works through AMPK, not NAD+-dependent pathways
- Only 5-Amino-1MQ modulates NAD+ bioavailability
- Effect on Insulin Sensitivity
- Indirect improvement via NAD+-mediated mitochondrial function and sirtuin activation
- Direct improvement via AMPK-mediated GLUT4 translocation. 25–35% increase in glucose uptake (independent of insulin)
- MOTS-c has more direct, acute insulin-sensitizing effects
- Fat Loss Pathway
- Sirtuin-mediated upregulation of PGC-1α → mitochondrial biogenesis → fatty acid oxidation (requires caloric deficit or exercise)
- AMPK-mediated ACC inhibition (blocks fat synthesis) + CPT1 activation (increases fat oxidation)
- Both support fat oxidation but through completely different signaling cascades
- Timeline to Observable Effect
- 10–14 days in rodent models (fat mass reduction, increased VO2)
- 7 days for insulin sensitivity; acute OGTT improvement within hours of single dose
- MOTS-c acts faster for glucose metabolism; 5-Amino-1MQ requires time for NAD+ restoration
- Typical Research Dose Range
- 50–100 mg/kg body weight in rodent models (human equivalent dose not established. Research compound only)
- 0.5–5 mg/kg subcutaneous in animal models; 15 mg single dose in human pilot trials
- Dosing not comparable. Different molecular weights and administration routes
- Administration Route
- Typically intraperitoneal (IP) or oral in preclinical models
- Subcutaneous or intravenous injection (peptide. Not orally bioavailable)
- Route determines bioavailability. MOTS-c requires injection; 5-Amino-1MQ can be oral
- Half-Life
- Not extensively characterized. Presumed short (metabolized hepatically)
- Approximately 2–4 hours in circulation (peptide degradation by proteases)
- Both likely require daily or twice-daily dosing in sustained protocols
- Storage Requirements
- Lyophilized powder stored at −20°C; reconstituted solutions refrigerated at 2–8°C, use within 30 days
- Lyophilized powder at −20°C; once reconstituted with bacteriostatic water, refrigerate at 2–8°C, use within 28 days
- Standard peptide storage applies to both. Temperature control critical